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Summary. Background: Increasedplasminogenactivator inhib-
itor (PAI-1) levels lead to impaired ﬁbrinolytic function
associated with higher cardiovascular risk. PAI-1 expression
may be regulated by diﬀerent inﬂammatory cytokines such as
interleukin-1a (IL-1). Several polymorphisms have been des-
cribed in thePAI-1 gene.Aim:Weexamined the inﬂuence of the
4G/5Gpolymorphism in the promoter regionon IL-1a-induced
PAI-1 expression by human umbilical vein endothelial cells
(HUVEC) in presence or absence of pravastatin.Methods and
results: Genotyped HUVEC were incubated with IL-1a
(500 U mL)1) in presence or absence of pravastatin (1–
10 lM). PAI-1 expressionwas analyzed by real time polymerase
chain reaction (PCR), and PAI-1 antigen measured in supern-
atants by ELISA. IL-1a increased PAI-1 secretion in a
genotype-dependent manner, and higher values were observed
for 4G/4G compared with both 4G/5G and 5G/5G cultures
(P < 0.05). Preincubation of HUVEC with 10 lM pravastatin
signiﬁcantly reduced IL-1-induced PAI-1 expression in 4G/4G
HUVEC compared with untreated cultures (177.5% ± 24.5%
vs. 257.9% ± 39.0%, P < 0.05). Pravastatin also attenuated
the amount of secreted PAI-1 by 4G/4G HUVEC after IL-1
stimulation (5020.6 ± 165.7 ng mL)1 vs. 4261.1 ±
309.8 ng mL)1, P < 0.05). This eﬀect was prevented by
coincubation with mevalonate, indicating a dependence on
HMG-CoA reductase inhibition. Conclusions: The endothelial
4G/5G PAI-1 genotype inﬂuences the PAI-1 response to IL-1a
and the modulatory eﬀect of pravastatin. As increased PAI-1
levels have been linked to cardiovascular disease the observed
endothelial modulation by pravastatin may have potential
clinical implications.
Keywords: ﬁbrinolysis, interleukin-1, plasminogen activator
inhibitor-1, polymorphism, pravastatin.
Introduction
Atherosclerosis can now be understood as a chronic inﬂam-
matory disease of the arterial system. Of particular interest is
the potential direct pathogenic role of non-speciﬁc circulating
acute phase markers of inﬂammation, such as C-reactive
protein, interleukin-1 (IL-1) and interleukin-6, and tumor
necrosis factor (TNF)-a [1]. Elevated plasminogen activator
inhibitor-1 (PAI-1) is considered a potential risk factor for
cardiovascular disease because of its role as inhibitor of
ﬁbrinolysis activation [2,3]. A pivotal role of PAI-1 in
atherothrombosis has been demonstrated both at experimental
and clinical levels [4–6].
Regulation of PAI-1 is a complex process, mainly occurring
at the level of gene transcription. PAI-1 is produced by different
cell types including endothelial cells (EC), hepatocytes, adipo-
cytes, and multiple regulatory factors have been identiﬁed that
play a role in PAI-1 transcription, for example, growth factors,
hormones, glucose, insulin, TNF-a, and glucocorticoids [7–11].
It has also been considered as an acute-phase protein, as PAI-1
levels strongly increase in response to inﬂammation or injury
[12].
Both metabolic and genetic factors determine circulating
PAI-1 levels [13]. Nine different polymorphisms have been
detected in the PAI-1 gene, the most extensively studied being
the 4G/5G polymorphism in the promoter [14]. This poly-
morphism refers to a guanosine deletion/insertion 675 bp
upstream from the start of the transcription. IL-1 is known to
up-regulate PAI-1 expression by different vascular cell types
[15]. In transfectedHepG2 cell line it was demonstrated that the
4G allele produced sixfold more mRNA than the 5G allele in
response to IL-1 because of an additional binding site (onto 5G
allele) for a DNA-binding protein that could be a transcrip-
tional repressor [16]. We have previously shown that the 4G/
5G polymorphism determines a differential response to athero-
genic stimuli [17].
Statin therapy has been shown to provide signiﬁcant
reduction in the levels of inﬂammatory markers [18]. The
clinical beneﬁts of statins are, however, not strictly correlated to
their lipid-lowering effects, and it is proposed that they have
pleiotropic effects derived from altered vascular function
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favoring ﬁbrinolysis [19]. Several in vitro and in vivo studies
suggest that statins exert part of their beneﬁcial effects through
reductions in PAI-1 levels [20–22].
Both PAI-1 and the 4G/5G polymorphism have been
studied extensively in relation to cardiovascular risk
[4,5,23,24]; however, little is known about either the endothelial
response of PAI-1 upon inﬂammatory stimuli in relation to the
4G/5G genotype [25], or the inﬂuence of this polymorphism on
PAI-1 modulation by statins.
We therefore examined the inﬂuence of the 4G/5G genotype
on IL-1a-induced PAI-1 expression by human umbilieal vein
endothelial cells (HUVEC) in presence or absence of pra-
vastatin to determine whether it modulates EC production of
PAI-1 in a genotype-speciﬁc manner.
Material and methods
Experimental design
HUVEC were isolated from umbilical cords obtained less than
8 h after delivery, by digestionwith collagenaseA (Gibco BRL,
Prat de Llobregat, Spain) as previously described [26]. All
studies were performed with conﬂuent cultures in the second
passage.CellswerewashedwithHank’s buffered saline solution
(HBSS) (Gibco) after which fresh serum-free media (Gibco)
supplemented with penicillin/streptomycin (Gibco) was added
(1%). Cultures were challenged with 500 U mL)1 IL-1a
(Amersham Pharmacia Biotech, Piscataway, NJ, USA) alone
or in the presence of 1 and 10 lM pravastatin (kindly provided
by Lawrence Laboratories, Berkeley, CA, USA) for 18 h, and
supernatants and cells were harvested at 0, 2, 6 and 24 h after
treatment. Dose of IL-1a was chosen according to a previous
report from our group [15]. Unstimulated cultures were used as
controls. Additional experiments were performed by simulta-
neous incubation of 10 lM pravastatin and 100 lMmevalonate
(DL-Mevalonic acid lactone; Sigma Aldrich, Madrid, Spain),
to determine whether the effect of statin on PAI-1 expression
was dependent on HMG-CoA reductase inhibition. Endothel-
ial cells from six umbilical cords/genotype were used for each
experimental condition.
In all experiments cellular viability (> 95%) was assessed by
Trypan Blue staining.
PAI-1 promoter 4G/5G genotype
Genomic DNA was extracted from cord tissue samples using
the TriPure Isolation Reagent (Roche, Marburg, Germany)
following themanufacturer’s instructions. The PAI-1 promoter
4G/5G polymorphism was analyzed with an allele-speciﬁc
polymerase chain reaction (PCR) [27].
RNA isolation and real-time quantitative RT-PCR
Total RNA was extracted from cells with TriPure (Roche) and
quantiﬁed with ultraviolet spectroscopy. Total RNA (0.5 lg)
was reverse transcribed and ampliﬁed by quantitative real time
PCR (ABI PRISM 7000 Detection System, Applied Biosys-
tems, Foster City, CA, USA). All samples were assayed in
triplicate and normalized on the basis of their b-actin content as
previously described [17].
Determination of PAI-1 antigen
PAI-1 antigen levels were measured in culture supernatants by
ELISA (Asserachrom-PAI-1, Diagnostica Stago, Asnie`res,
France) according to manufacturer’s instructions and values
expressed as ng mL)1. Inter- and intra-assay coefﬁcients of
variation were < 8%.
Statistical analysis
Results regarding HUVEC are expressed as mean ± SEM of
six independent experiments for each PAI-1 genotype. PAI-1
expression at 2, 6 and 24 h after stimulation was expressed as
percentage of baseline value, whichwas considered 100%. PAI-
1 antigen analysis was performed based on absolute levels.
Statistical analysis was performed by one-way ANOVA followed
by Bonferroni test for comparisons among genotypes. Differ-
ences between stimulated and unstimulated cultures of the
same genotype were assessed by Mann–Whitney U-test, and
Wilcoxon’s test was used for paired data. To test whether there
were signiﬁcant treatment related genotype-speciﬁc differences
in PAI-1 mRNA and antigen levels, a two-way ANOVA analysis
was used. Differences were considered statistically signiﬁcant at
P < 0.05. The statistical analysis was performed with SPSS for
Windows software package version 11.0 (SPSS, Chicago, IL,
USA).
Results
Influence of the 4G/5G polymorphism on IL-1-induced PAI-1
expression by HUVEC
PAI-1 genotyped HUVEC were stimulated with 500 U mL)1
IL-1a in the presence and absence of pravastin, and PAI-1
mRNA and protein levels measured before and 2, 6 and 24 h
after stimulation. As shown in Table 1, the endothelial PAI-1
expression and secretion were modiﬁed by treatment (cytokine
alone or in combination with statin) in a genotype-dependent
manner.
PAI-1 expression was elevated 2, 6 and 24 h after IL-1
stimulation for all genotypes compared with non-stimulated
cultures (Table 2). This increase in mRNA levels showed a
non-signiﬁcant trend in 4G/4G cultures throughout the
experiment, although signiﬁcantly higher levels were found at
2 h in 4G/5G HUVEC allele in relation to 5G/5G (P < 0.05).
As shown in Table 3, the effect of IL-1a on PAI-1 expression
in all HUVEC genotypes was accompanied by an increase of
PAI-1 antigen levels 2, 6 and 24 h after stimulation when
compared with control cultures (P < 0.05). However, a higher
induction of PAI-1 protein was observed during the experiment
in 4G/4G HUVEC compared with the remaining genotypes
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(P < 0.05). IL-1 stimulated cultures homozygous for 4G
showed an earlier and time-dependent increase of secreted PAI-
1 compared with either heterozygotes or 5G/5G HUVEC
(P < 0.05). Moreover, the 4G/5G cultures also had increased
PAI-1 antigen levels when compared with homozygous for 5G
allele (1250.3 ± 64.7 ng mL)1 vs. 862.0 ± 34.7 ng mL)1 at
2 h, P < 0.05).
Effect of pravastatin on IL-1 induced PAI-1 response
by HUVEC
Further analyses were performed to evaluate the modulatory
effect of pravastatin on IL-1a-induced PAI-1 expression by
HUVEC. As already mentioned, IL-1-induced PAI-1 expres-
sion and secretion were modiﬁed by the treatment statin in a
genotype-dependent manner at 2, 6 and 24 h.
Pravastatin modulated PAI-1 expression and secretion in
dose-dependent manner, the higher dose (10 lM) being the
most effective to reduce inhibitor levels in 4G/4G and 4G/5G
HUVEC, with no effect in 5G/5G cultures (Tables 2 and 3).
Preincubationwith 10 lMpravastatin signiﬁcantly decreased
PAI-1 expression 2 h after IL-1 stimulation (177.5% ± 24.5%
vs. 257.9% ± 39.0%, P < 0.05) only in 4G/4G cultures
(Table 2). Statin treatment also reduced PAI-1 antigen levels
throughout the experiment (P < 0.001) in 4G/4G HUVEC.
Furthermore, both doses of pravastatin diminished PAI-1
levels at 2 h in 4G/5G HUVEC (1250.3 ± 64.7 ng mL)1 vs.
971.4 ± 19.6 ng mL)1 and 872.3 ± 32.4 ng mL)1 respect-
ively, P < 0.05), an effect not observed in 5G/5G cultures
(Table 3). Additional experiments were performed to assess
whether the effect of pravastatin was dependent onHMG-CoA
reductase inhibition. 4G/4G HUVEC were coincubated with
10 lM pravastatin and 100 lM mevalonate, 18 h before
stimulation with IL-1a. In the presence of mevalonate,
pravastatin neither prevented the increase of PAI-1 antigen
levels induced by IL-1a, nor the PAI-1 expression when
compared with cytokine-stimulated HUVEC (Fig. 1).
Discussion
We showed that the endothelial 4G/5G PAI-1 polymorphism
determines a signiﬁcant association to PAI-1 levels upon
inﬂammatory stimuli, and that pravastatin reduces IL-1
induced PAI-1 in a genotype-dependent manner, which was
dependent on HMG-CoA reductase inhibition. Our results
support a role for the 4G/5G PAI-1 polymorphism in
determining both PAI-1 response to inﬂammatory stimuli
and modulation by statins.
We found increased PAI-1 expression in HUVEC with 4G
allele after IL-1 stimulation compared with 5G/5G cultures,
and a different protein pattern, as secreted PAI-1 levels were
signiﬁcantly increased in 4G/4G HUVEC (13–40%) when
compared with either 4G/5G or 5G/5G cultures. PAI-1 acts as
an important down-regulator of ﬁbrinolysis and promotes
Table 2 Plasminogen activator inhibitor-1 expression in genotyped human umbilical vein endothelial cells stimulated with interleukin-1a (IL-a) in presence
of pravastatin. Values (mean ± SEM) are expressed as percentage of baseline
Non-stimulated, n ¼ 6 IL-1, n ¼ 6 Pravastatin 1 lM + IL-1, n ¼ 6 Pravastatin 10 lM + IL-1, n ¼ 6
2 h
4G/4G 100.1 ± 1.6 257.9 ± 39.0* 200.1 ± 39.3 177.5 ± 24.5
4G/5G 102.0 ± 1.7 288.9 ± 40.7*** 229.5 ± 66.6 196.2 ± 40.0
5G/5G 97.8 ± 2.2 182.4 ± 16.3* 166.7 ± 15.5 154.6 ± 30.5
6 h
4G/4G 98.5 ± 2.1 255.0 ± 33.5* 250.9 ± 59.2 252.5 ± 42.9
4G/5G 97.3 ± 3.2 247.6 ± 32.5* 289.9 ± 83.4 255.4 ± 26.7
5G/5G 101.4 ± 2.5 231.9 ± 30.4* 435.6 ± 73.5 249.1 ± 37.8
24 h
4G/4G 98.8 ± 0.3 321.0 ± 52.0* 230.8 ± 53.3 208.9 ± 38.1
4G/5G 98.4 ± 1.2 219.6 ± 42.5* 344.2 ± 17.0 345.2 ± 25.9
5G/5G 100.1 ± 0.3 273.3 ± 34.7* 428.0 ± 58.6 184.6 ± 39.4
*P < 0.05 compared with non-stimulated (post hoc Bonferroni test). P < 0.01 compared with baseline (post hoc Bonferroni test). **P < 0.05
compared with IL-1 stimulated 5G/5G HUVEC (post hoc Bonferroni test).  P < 0.05 compared with IL-1 (post hoc Bonferroni test).
Table 1 Two-way ANOVA analysis
PAI-1 mRNA PAI-1 antigen
F-ratio P F-ratio P
Basal
Treatment – – 11.52 <0.001
Genotype – – 0.28 NS
Interaction – – 1.94 NS
2 h
Treatment 4.12 0.012 10.12 <0.001
Genotype 1.27 <0.001 11.88 <0.001
Interaction 0.25 NS 10.39 <0.001
6 h
Treatment 6.07 0.001 25.28 <0.001
Genotype 0.53 NS 7.13 0.001
Interaction 1.11 NS 5.81 <0.001
24 h
Treatment 9.29 <0.001 50.82 <0.001
Genotype 0.66 NS 0.62 NS
Interaction 3.11 0.014 2.36 0.021
Treatment groups ¼ control, IL-1, pravastatin, IL-1 + pravastatin.
Genotypes ¼ 4G/4G, 4G/5G, 5G/5G. Interaction ¼ geno-
type · treatment interaction. PAI, plasminogen activator inhibitor.
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deposition of ﬁbrin within the vascular system [2,3,12]. Several
inﬂammatory stimuli, including IL-1, are known to induce
PAI-1 expression in different cells types [7,9,15,28]; however,
little is known about the inﬂuence of the 4G/5G genotypes in
relation to cytokine stimulation by human ECs. Whereas in
transfected HepG2 cell line the 4G allele showed a marked
increase of PAI-1mRNA in response to IL-1 [16], other reports
found no association between the 4G/5G genotype and
cytokine-induced PAI-1 expression by either HUVEC or
smooth muscle cells (SMC) [25,29].
We show herein that endothelial PAI-1 expression in
response to IL-1a was associated to the 4G allele. Our results
agree with Dawson et al., who observed a marked increase of
PAI-1 mRNA in response to IL-1 in transfected HepG2 cell
line in relation to the 4G allele. It has been described that after
IL-1 stimulation, a transcriptionally active NF-jB binds both
4G and 5G alleles, but the 5G sequence of the PAI-1 promoter
also binds an inactive subunit keeping PAI-1 levels as baseline
[14,16].
Additional experiments were performed to determine the
modulatory effect of pravastatin on cytokine-induced endo-
thelial PAI-1 in relation to 4G/5G genotypes.
Pravastatin signiﬁcantly prevented the IL-1 induced PAI-1
expression at 2 h and protein secretion at 2, 6 and 24 h in a
genotype-dependent manner, so that the reduction was
observed mainly in 4G/4G ECs. We also show that such effect
was dependent on HMG-CoA reductase inhibition, because it
was prevented in the presence of mevalonate.
It has been generally assumed that cholesterol reduction by
statins is the predominant mechanism underlying their bene-
ﬁcial effects in cardiovascular diseases [30]. Statins inhibit
HMG-CoA reductase, the enzyme that converts HMG-CoA
into mevalonic acid, a cholesterol precursor. By inhibiting L-
mevalonic acid synthesis, statins also prevent the synthesis of
important isoprenoid intermediates of the cholesterol biosyn-
thetic pathway, such as farnesyl pyrophosphate and geraryl-
geranyl pyrophosphate, which are implicated in the activation
of other protein families relevant for endothelial function and
also in the maintenance of the ﬁbrinolytic balance [19,31].
In vitro studies with different statins have shown a reduction
in PAI-1 levels in human EC, SMC and monocytes induced by
IL-1 (500 U mL–1)
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Fig. 1. Eﬀect of pravastatin and mevalonate on interleukin-1-induced
plasminogen activator inhibitor (PAI)-1 expression and secretion in 4G/
4G human umbilical vein endothelial cells. The time course at 0, 2, 6 and
24 h after stimulation is shown. (A) PAI-1mRNA expressionmeasured by
real time polymerase chain reaction and expressed as percentage of base-
line (mean ± SEM). (B) PAI-1 antigen levels expressed as ng mL)1
(mean ± SEM). §§P < 0.05 compared with IL-1; ***P < 0.05
compared with mevalonate.
Table 3 Plasminogen activator inhibitor-1 antigen levels (ng mL)1) in genotyped human umbilical vein endothelial cells stimulated with IL-1a in presence
of pravastatin (mean ± SEM)
Non-stimulated, n ¼ 6 IL-1, n ¼ 6 Pravastatin 1 lM + IL-1, n ¼ 6 Pravastatin 10 lM + IL-1, n ¼ 6
Baseline
4G/4G 698.9 ± 9.0 1283.0 ± 54.8* 1207.7 ± 56.6 1138.6 ± 23.0
4G/5G 930.5 ± 72.2 1024.7 ± 78.5** 1198.7 ± 143.5 1163.3 ± 38.2
5G/5G 758.0 ± 82.9 1189.8 ± 73.1* 1108.8 ± 140.5 1441.2 ± 284.8
2 h
4G/4G 1005.2 ± 81.4 1435.5 ± 59.6* 1290.4 ± 59.9 1224.6 ± 37.9
4G/5G 1060.8 ± 35.5 1250.3 ± 64.7*** 971.4 ± 19.6 872.3 ± 32.4
5G/5G 848.8 ± 52.2 862.0 ± 34.7** 1444.4 ± 83.2 978.0 ± 40.2
6 h
4G/4G 1304.0 ± 56.0 2235.2 ± 106.0* 2117.1 ± 74.3 1869.5 ± 73.4
4G/5G 1608.6 ± 126.0 1839.5 ± 140.9** 1980.9 ± 112.5 1817.8 ± 102.3
5G/5G 822.2 ± 97.4 1595.5 ± 96.1*** 1841.0 ± 45.0 2169.3 ± 77.4
24 h
4G/4G 2354.1 ± 166.8 5020.6 ± 165.7* 4118.1 ± 161.8 4261.1 ± 309.8
4G/5G 2833.0 ± 174.1 4299.8 ± 272.7*** 4121.2 ± 370.2 4426.9 ± 284.4
5G/5G 2367.7 ± 181.4 4422.6 ± 170.2*** 5132.4 ± 255.1 4924. 6 ± 479.1
*P < 0.05 compared with non-stimulated (post hoc Bonferroni test). P < 0.01 compared with baseline (post hoc Bonferroni test). **P < 0.05
compared with IL-1 stimulated 4G/4G HUVEC (post hoc Bonferroni test). P < 0.05 compared with IL-1 (post hoc Bonferroni test).
Endothelial PAI-1 genotypes and statin therapy 1801
 2006 International Society on Thrombosis and Haemostasis
proinﬂammatory and proatherogenic agents [22,32–35]. De-
spite the hydrophilicity of pravastatin causing poor penetration
into cells, a recent report suggests that pravastatin suppresses
the synthesis of PAI-1 in human monocytes, probably by
preventing geranylgeranylation of Rho proteins [34], thus
decreasing the activation of transcription factors like NF-jB or
AP-1 [22,36]; moreover, other study has also demonstrated that
pravastatin-reduced NF-jB activity in EC [37], which might
partially explain the preferential PAI-1 reduction in 4G/4G
HUVEC. The potential clinical implications of statin pleiotro-
py suggest that perhaps other biomarkers, in addition to lipid
levels, should be used to asses the efﬁcacy of statin therapy in
patients with cardiovascular risk. Our results also emphasize
the potential beneﬁcial effects of statin therapy in inﬂammatory
conditions such as atherosclerosis.
Some limitations of the present studymust be recognized. As
only PAI-1 was analyzed, the net endothelial ﬁbrinolytic
balance in response to IL-1 in relation to the 4G/5G genotype
could not be assessed. Additional studies are also needed to
examine how IL-1 might inﬂuence PAI-1 at the promoter level
by other cell types (e.g. adult EC, adipocytes). Given the
unclear role of ECs as a source for circulating PAI-1 in humans
an effect of this polymorphism on other cell types, such as
hepatocytes and platelets cannot be ruled out [7,38].
In conclusion, we report that the endothelial 4G/5G PAI-1
polymorphism is signiﬁcantly associated with the PAI-1
response to IL-1 in vitro, which can be prevented in the presence
of pravastatin. As increased PAI-1 levels have been linked to
cardiovascular disease, the observed endothelial modulation by
pravastatin may have potential clinical implications.
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